Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
Radiation Oncology Journal. 2016;34(1):1-9 
Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: a case report and literature review
. 2022;
Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives
Breast Care. 2020;15(6):570-578
Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
Breast Cancer. 2013;20(2):103-110
Expanding Treatment Arsenal for Oestrogen Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Hong Kong Journal of Radiology. 2019;22(2):86-97
Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review
Frontiers in Oncology. 2022;12:
Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
Cancers. 2022;14(20):5136
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Cancer Management and Research. 2016;Volume 8:85-94
Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
OncoTargets and Therapy. 2016;Volume 9:6119-6125
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Cancer Management and Research. 2016;Volume 8:127-128